Tagged with TEVA

Ukraine Dmytro Spitsyn, General Manager of Teva Ukraine, which proudly stands as the largest international company operating in the country, documents the challenges he faced and the strategies he implemented to overcome the 2013 crisis in Ukraine, while Teva has been positioning itself as a company committed to increasing life expectancy…

Singapore Teva’s recently appointed SVP of APAC and MENA Vivek Bachhawat details his relatively seamless journey from Actavis to Teva and the synergies inherent in both organizations even prior to the merger. He also highlights the company’s continued commitment to Singapore and its key regional role which will grow in importance…

Generics Andreas Bosshard of Mepha-Teva in Switzerland describes Switzerland’s unique generics market, the quality of the Mepha-Teva brand, innovations within generics, and the company’s growth strategy within the Swiss market. It has been five years since the merger of Teva and Mepha in Switzerland, and curiously the brand name Mepha remains in…

Czech Republic A current lack of transparency in Czech healthcare spending is severely detrimental to all industry stakeholders. However, new synergies between the private and public sectors are helping to clear these murky waters.   The Czech Republic, with a population of about 10.5 million, is the third most populous country within Central…

Pharma Teva Czech Republic & Slovakia GM Juan Carlos Conde describes how the Czech Republic hosts Teva’s third largest manufacturing site within Europe and the recent implementation of a more efficient cluster organization covering the Czech and Slovakian markets. You became general manager of Teva Pharmaceuticals Czech Republic & Slovakia eight…

Pharma Teva Benelux and Nordics’ GM lifts the lid on how the company has grown to become the market leader in the Netherlands. Looking at Teva’s activities, your market leader position in the Netherlands and your global ambitions, a truly ambitious culture emanates from TEVA’s achievements. Where does this drive come from?…

Generics The president & CEO of Canada’s largest generics player considers the current market dynamics for generic products, including IP regulation, generic penetration, and the advantages of balancing branded and non-branded products.  What was the strategy behind the integration of Novopharm into Teva? Novopharm is one of the pioneers in the…

Teva Ratiopharm Austria Dr Spatz, what would you highlight as the main specificities of the Austrian generic market, and explain how Teva has adapted its approach to the Austrian environment? Teva recently changed directions in its development, determined to be a multifaceted company, offering to the market not only generics but also branded…

Teva Ukraine Since 2006 Teva has been on a solid phase of growth and consolidation, mainly through the acquisitions of IVAX in 2006, Pliva (Barr) in 2008 and ratiopharm in 2010, which have transformed the company from the number 40 global pharmaceutical player to a top-10 pharma company today. As the person…

Teva Czech Republic Mr. Zahradnik, you have long been an active member of the Czech generic drug makers’ association CAFF (Czech Association of Pharmaceutical Firms), chairing the organization. Dr. Zörner, executive director of the CAFF, has remarked that the Czech Republic is a challenging market, but also one in which the authorities have…

Teva France We have had the chance to interview a number of Teva’s subsidiaries in Europe, and witnessed how each of them has dealt with the strong transformations that the group has experienced in the last four years. For instance, Mr. Dethlefs from Teva Germany highlighted the challenge in harmonizing five different…

Teva Italy Mr. Medda, Teva’s Italian history is relatively young, could you describe the main facts that describe Teva presence in Italy? Teva Italia was founded in 1996 and is currently the leading generic pharmaceutical company in Italy. So, the company has experienced rapid growth in the emerging generic market over the…